3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Phase 1
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
1
Dermatologic
1
Conditions
Melanoma
3
Triple Negative Breast Neoplasms
2
Pancreatic Neoplasms
2
Carcinoma, Squamous Cell
2
Carcinoma, Merkel Cell
2
Breast Neoplasms
2
Squamous Cell Carcinoma of Head and Neck
1
Sarcoma
1
Rectal Neoplasms
1
Peritoneal Neoplasms
1
Neurofibromatosis 1
1
Neurofibromatoses
1
Neurofibroma
1
Neoplasm Metastasis
1
Mycosis Fungoides
1
Lymphoma, T-Cell, Cutaneous
1
Colorectal Neoplasms
1
Carcinoma, Basal Cell
1
Breast Carcinoma In Situ
1
Advanced Non CNS Tumors
1
Adenocarcinoma
1
Interventions
romidepsin
12
Cyclophosphamide
10
fludarabine phosphate
7
Peripheral Blood Stem Cell Transplantation
7
Gemcitabine
7
Bortezomib
7
fludarabine
6
Lenalidomide
6
Filgrastim
6
tanespimycin
5
Vorinostat
5
Magnetic Resonance Spectroscopy
5
Etoposide
5
Biopsy
5
belinostat
4
Tacrolimus
4
Depsipeptides
4
Brentuximab Vedotin
4
Whole-Body Irradiation
3
Specimen Handling
3
Radiotherapy
3
Oxaliplatin
3
Nivolumab
3
Methylprednisolone
3
Lactones
3
Irinotecan
3
Ipilimumab
3
Doxorubicin
3
Dexamethasone
3
Dasatinib
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1
×
Lymphoma, T-Cell, Cutaneous
×
talimogene laherparepvec
×
Clear all
NCT03458117
2022-03-18
20139157 T-VEC
University of Zurich
Phase 1
Completed
26 enrolled